Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
100.79
-1.76 (-1.72%)
Dec 5, 2025, 4:00 PM EST - Market closed
Revvity Revenue
Revvity had revenue of $698.95M in the quarter ending September 28, 2025, with 2.18% growth. This brings the company's revenue in the last twelve months to $2.81B, up 3.37% year-over-year. In the year 2024, Revvity had annual revenue of $2.76B with 0.16% growth.
Revenue (ttm)
$2.81B
Revenue Growth
+3.37%
P/S Ratio
4.25
Revenue / Employee
$255,761
Employees
11,000
Market Cap
11.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 2.76B | 4.46M | 0.16% |
| Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
| Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
| Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
| Jan 3, 2021 | 2.66B | -220.44M | -7.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RVTY News
- 3 days ago - Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 17 days ago - Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 25 days ago - Revvity, Inc. (RVTY) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 25 days ago - Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy - Business Wire
- 25 days ago - Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities - Business Wire
- 5 weeks ago - Revvity Analysts Increase Their Forecasts After Q3 Earnings - Benzinga
- 5 weeks ago - Revvity to Present at Upcoming Investor Conferences - Business Wire
- 5 weeks ago - Revvity: Software Momentum And Screening Offset China Weakness - Seeking Alpha